0001567619-20-012131.txt : 20200615
0001567619-20-012131.hdr.sgml : 20200615
20200615151540
ACCESSION NUMBER: 0001567619-20-012131
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200611
FILED AS OF DATE: 20200615
DATE AS OF CHANGE: 20200615
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Smither John W
CENTRAL INDEX KEY: 0001559583
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39186
FILM NUMBER: 20963061
MAIL ADDRESS:
STREET 1: C/O KYTHERA BIOPHARMACEUTICALS, INC.
STREET 2: 27200 WEST AGOURA ROAD, SUITE 200
CITY: CALABASAS
STATE: CA
ZIP: 91301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Arcutis Biotherapeutics, Inc.
CENTRAL INDEX KEY: 0001787306
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 812974255
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2945 TOWNSGATE ROAD
STREET 2: SUITE 110
CITY: WESTLAKE VILLAGE
STATE: CA
ZIP: 91361
BUSINESS PHONE: 805-418-5006
MAIL ADDRESS:
STREET 1: 2945 TOWNSGATE ROAD
STREET 2: SUITE 110
CITY: WESTLAKE VILLAGE
STATE: CA
ZIP: 91361
FORMER COMPANY:
FORMER CONFORMED NAME: Arcutis, Inc.
DATE OF NAME CHANGE: 20190905
4
1
doc1.xml
FORM 4
X0306
4
2020-06-11
0
0001787306
Arcutis Biotherapeutics, Inc.
ARQT
0001559583
Smither John W
C/O ARCUTIS BIOTHERAPEUTICS, INC.
2945 TOWNSGATE ROAD, SUITE 110
WESTLAKE VILLAGE
CA
91361
0
1
0
0
Chief Financial Officer
Common Stock
2020-06-11
4
M
0
14875
1.6806
A
123840
D
Stock Option (Right to Buy)
1.6806
2020-06-11
4
M
0
14875
0
D
2029-05-14
Common Stock
14875
110080
D
Reflects cash exercise of stock option without the disposition of the underlying shares.
Includes 9,000 Restricted Stock Units ("RSUs"). The RSUs vest annually in equal installments over a period of 4 years commencing on the grant date, so that 100% of the RSUs become fully vested on February 27, 2024.
The option vests as to 1/4 of the total shares on May 1, 2020, and then 1/48 of the total shares vest monthly thereafter, with 100% of the total shares vested and exercisable on May 1, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.
/s/ John W. Smither
2020-06-15